Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Structure Therapeutics, Inc. Sponsored ADR (GPCR) vs. Competitors

1,314 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
GPCRStructure Therapeutics, Inc. Sponsored ADR$17.36$1.30B-4.66-49.68%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumGPCRUnlock the GPCR top-analyst price target with TipRanks Premium
LXRXLexicon Pharmaceuticals$1.72$792.52M-12.2817.01%Strong BuyUnlock the LXRX analyst price target with TipRanks PremiumGPCR vs LXRXUnlock the LXRX top-analyst price target with TipRanks Premium
VKTXViking Therapeutics$26.17$3.43B-4.98-30.69%Strong BuyUnlock the VKTX analyst price target with TipRanks PremiumGPCR vs VKTXUnlock the VKTX top-analyst price target with TipRanks Premium
MBXMBX Biosciences, Inc.$53.42$2.64B-17.19102.66%Strong BuyUnlock the MBX analyst price target with TipRanks PremiumGPCR vs MBXUnlock the MBX top-analyst price target with TipRanks Premium
SEPNSepterna, Inc.$39.45$1.90B-30.7781.88%Strong BuyUnlock the SEPN analyst price target with TipRanks PremiumGPCR vs SEPNUnlock the SEPN top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$11.79$1.58B-4.00-54.65%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumGPCR vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
GPCRStructure Therapeutics, Inc. Sponsored ADR17.36-19.15-52.45%
LXRXLexicon Pharmaceuticals1.720.2718.62%
VKTXViking Therapeutics26.17-9.87-27.39%
MBXMBX Biosciences, Inc.53.4226.0395.03%
SEPNSepterna, Inc.39.4516.3570.78%
KLRAKailera Therapeutics, Inc.11.79-14.21-54.65%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts